{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T16:20:58Z","timestamp":1792686058720,"version":"4.5.0"},"reference-count":88,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Endocrinology & Metabolism"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.beem.2022.101631","type":"journal-article","created":{"date-parts":[[2022,2,23]],"date-time":"2022-02-23T22:05:12Z","timestamp":1645653912000},"page":"101631","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Long-term thionamide antithyroid treatment of Graves' disease"],"prefix":"10.1016","volume":"37","author":[{"given":"Fereidoun","family":"Azizi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hengameh","family":"Abdi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atieh","family":"Amouzegar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali Siamak","family":"Habibi Moeini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.beem.2022.101631_bib1","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1056\/NEJMra1510030","article-title":"Graves' disease","volume":"375","author":"Smith","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.beem.2022.101631_bib2","article-title":"Graves' disease (primer)","volume":"6","author":"Davies","year":"2020","journal-title":"Nat Rev Dis Prim"},{"key":"10.1016\/j.beem.2022.101631_bib3","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1210\/jcem-70-3-675","article-title":"Antithyroid drugs and Graves' disease: a prospective randomized evaluation of the efficacy of treatment duration","volume":"70","author":"Allannic","year":"1990","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2022.101631_bib4","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1089\/thy.1991.1.129","article-title":"Differences and similarities in the diagnosis and treatment of Graves' disease in Europe, Japan, and the United States","volume":"1","author":"Wartofsky","year":"1991","journal-title":"Thyroid"},{"key":"10.1016\/j.beem.2022.101631_bib5","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1089\/thy.2019.0132","article-title":"Patterns of use, efficacy, and safety of treatment options for patients with Graves' disease: a nationwide population-based study","volume":"30","author":"Brito","year":"2020","journal-title":"Thyroid"},{"key":"10.1016\/j.beem.2022.101631_bib6","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1055\/s-0035-1555759","article-title":"Outcome prediction of treatment of Graves' hyperthyroidism with antithyroid drugs","volume":"47","author":"Piantanida","year":"2015","journal-title":"Horm Metab Res"},{"key":"10.1016\/j.beem.2022.101631_bib7","doi-asserted-by":"crossref","DOI":"10.5812\/ijem.102346","article-title":"Prediction of relapse after antithyroid drugs withdrawal: a narrative review","volume":"18","author":"Wang","year":"2020","journal-title":"Int J Endocrinol Metabol"},{"key":"10.1016\/j.beem.2022.101631_bib8","doi-asserted-by":"crossref","first-page":"e1006","DOI":"10.1210\/clinem\/dgz292","article-title":"Prospective trial of functional thyrotropin receptor antibodies in Graves disease","volume":"105","author":"Kahaly","year":"2020","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2022.101631_bib9","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1089\/thy.2016.0229","article-title":"2016 American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis","volume":"26","author":"Ross","year":"2016","journal-title":"Thyroid"},{"key":"10.1016\/j.beem.2022.101631_bib10","series-title":"Antithyroid drug regimen for treating Graves' hyperthyroidism","author":"Abraham","year":"2010"},{"key":"10.1016\/j.beem.2022.101631_bib11","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1046\/j.1365-2265.1999.00629.x","article-title":"Antithyroid drugs and Graves' disease\u2014prospective randomized assessment of long-term treatment","volume":"50","author":"Maugendre","year":"1999","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.beem.2022.101631_bib12","first-page":"477","article-title":"Long-term continuous methimazole or radioiodine treatment for hyperthyroidism","volume":"15","author":"Azizi","year":"2012","journal-title":"Arch Iran Med"},{"key":"10.1016\/j.beem.2022.101631_bib13","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1089\/thy.2011.0039","article-title":"Sustained control of Graves' hyperthyroidism during long-term low-dose antithyroid drug therapy of patients with severe Graves' orbitopathy","volume":"21","author":"Laurberg","year":"2011","journal-title":"Thyroid"},{"key":"10.1016\/j.beem.2022.101631_bib14","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1089\/thy.2015.0195","article-title":"Outcomes in relapsed Graves' disease patients following radioiodine or prolonged low dose of methimazole treatment","volume":"25","author":"Villagelin","year":"2015","journal-title":"Thyroid"},{"key":"10.1016\/j.beem.2022.101631_bib15","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1089\/thy.2016.0652","article-title":"Long-term antithyroid drug treatment: a systematic review and meta-analysis","volume":"27","author":"Azizi","year":"2017","journal-title":"Thyroid"},{"key":"10.1016\/j.beem.2022.101631_bib16","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1007\/s40618-019-01054-1","article-title":"Safety of long-term antithyroid drug treatment? A systematic review","volume":"42","author":"Azizi","year":"2019","journal-title":"J\u00a0Endocrinol Invest"},{"key":"10.1016\/j.beem.2022.101631_bib17","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1089\/thy.2019.0180","article-title":"Increased remission rates after long-term methimazole therapy in patients with Graves' disease: results of a randomized clinical trial","volume":"29","author":"Azizi","year":"2019","journal-title":"Thyroid : official journal of the American Thyroid Association"},{"key":"10.1016\/j.beem.2022.101631_bib18","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2018-3034","article-title":"Long-term methimazole therapy in juvenile Graves' disease: a randomized trial","volume":"143","author":"Azizi","year":"2019","journal-title":"Pediatrics"},{"key":"10.1016\/j.beem.2022.101631_bib19","first-page":"1","article-title":"Appropriate duration of antithyroid drug treatment as a predictor for relapse of Graves' disease: a systematic scoping review","author":"Azizi","year":"2022","journal-title":"J\u00a0Endocrinol Invest"},{"key":"10.1016\/j.beem.2022.101631_bib20","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1001\/jama.1943.02840190008003","article-title":"Treatment of hyperthyroidism with thiourea and thiouracil","volume":"122","author":"Astwood","year":"1943","journal-title":"JAMA"},{"key":"10.1016\/j.beem.2022.101631_bib21","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1210\/jcem-11-3-298","article-title":"Late results from continuous treatment of thyrotoxicosis with methylthiouracil","volume":"11","author":"Iversen","year":"1951","journal-title":"J\u00a0Clin Endocrinol"},{"key":"10.1016\/j.beem.2022.101631_bib22","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1001\/jama.1953.03690030001001","article-title":"Prognosis of hyperthyroidism treated by antithyroid drugs","volume":"152","author":"Solomon","year":"1953","journal-title":"JAMA"},{"key":"10.1016\/j.beem.2022.101631_bib23","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1056\/NEJM194705152362002","article-title":"Persistence of remissions of thyrotoxicosis after cessation of thiouracil therapy","volume":"236","author":"Williams","year":"1947","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.beem.2022.101631_bib24","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1210\/jcem-8-10-866","article-title":"Propylthiouracil in the treatment of toxic goiter","volume":"8","author":"Reveno","year":"1948","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2022.101631_bib25","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1210\/jcem-12-6-719","article-title":"Therapeutic studies in hyperthyroidism: methylthiouracil","volume":"12","author":"Stirrett","year":"1952","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2022.101631_bib26","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1210\/jcem-26-8-803","article-title":"Long-term outcome of hyperthyroidism treated with antithyroid drugs","volume":"26","author":"Hershman","year":"1966","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2022.101631_bib27","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1001\/jama.1963.63710060036014","article-title":"Management of thyroid disorders","volume":"186","author":"Astwood","year":"1963","journal-title":"JAMA"},{"key":"10.1016\/j.beem.2022.101631_bib28","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1001\/jama.1979.03300220020015","article-title":"Long-term antithyroid treatment in hyperthyroidism","volume":"242","author":"Slingerland","year":"1979","journal-title":"JAMA"},{"key":"10.1016\/j.beem.2022.101631_bib29","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1210\/jcem-70-6-1518","article-title":"Current trends in the management of Graves' disease","volume":"70","author":"Solomon","year":"1990","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2022.101631_bib30","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1210\/jcem-30-4-540","article-title":"Prediction of the long-term results of antithyroid drug therapy for thyrotoxicosis","volume":"30","author":"Alexander","year":"1970","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2022.101631_bib31","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/j.1365-2265.1989.tb01244.x","article-title":"Antithyroid drugs in the treatment of hyperthyroidism of Graves' disease: long-term follow-up of 434 patients","volume":"31","author":"Hedley","year":"1989","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.beem.2022.101631_bib32","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1001\/archpedi.1987.04460100062026","article-title":"Remission in children with hyperthyroidism treated with propylthiouracil: long-term results","volume":"141","author":"Gorton","year":"1987","journal-title":"Am J Dis Child"},{"key":"10.1016\/j.beem.2022.101631_bib33","doi-asserted-by":"crossref","first-page":"488","DOI":"10.7326\/0003-4819-92-4-488","article-title":"Thionamide therapy in Graves' disease: relation of relapse rate to duration of therapy","volume":"92","author":"Tamai","year":"1980","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.beem.2022.101631_bib34","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S0889-8529(05)70308-X","article-title":"Antithyroid drugs for the treatment of hyperthyroidism caused by Graves' disease","volume":"27","author":"Cooper","year":"1998","journal-title":"Endocrinol Metab Clin N Am"},{"key":"10.1016\/j.beem.2022.101631_bib35","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1210\/jc.2009-0850","article-title":"Putting propylthiouracil in perspective","volume":"94","author":"Cooper","year":"2009","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2022.101631_bib36","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1530\/eje.1.01904","article-title":"Effect of long-term continuous methimazole treatment of hyperthyroidism: comparison with radioiodine","volume":"152","author":"Azizi","year":"2005","journal-title":"Eur J Endocrinol"},{"issue":"Suppl","key":"10.1016\/j.beem.2022.101631_bib37","doi-asserted-by":"crossref","DOI":"10.5812\/ijem.101139","article-title":"Long-term antithyroid drug treatment: trends in serum TSH and TSH receptor antibody changes in patients with Graves' disease","volume":"18","author":"Okamura","year":"2020","journal-title":"Int J Endocrinol Metabol"},{"key":"10.1016\/j.beem.2022.101631_bib38","doi-asserted-by":"crossref","first-page":"3704","DOI":"10.1210\/clinem\/dgaa646","article-title":"Management of graves thyroidal and extrathyroidal disease: an update","volume":"105","author":"Kahaly","year":"2020","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2022.101631_bib39","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1177\/003591576105401009","article-title":"Nonsurgical treatment of thyrotoxicosis","volume":"54","author":"Trotter","year":"1961","journal-title":"Proc Roy Soc Med"},{"key":"10.1016\/j.beem.2022.101631_bib40","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1507\/endocrj1954.17.327","article-title":"Long-term result of antithyroid drug therapy for grave's disease follow up after more than 5 years","volume":"17","author":"Shizume","year":"1970","journal-title":"Endocrinol Jpn"},{"key":"10.1016\/j.beem.2022.101631_bib41","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1007\/BF03346433","article-title":"Long-term follow-up of patients with hyperthyroidism due to Graves' disease treated with methimazole. Comparison of usual treatment schedule with drug discontinuation vs continuous treatment with low methimazole doses: a retrospective study","volume":"31","author":"Mazza","year":"2008","journal-title":"J\u00a0Endocrinol Invest"},{"key":"10.1016\/j.beem.2022.101631_bib42","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1089\/thy.2010.0181","article-title":"Outcome of very long-term treatment with antithyroid drugs in Graves' hyperthyroidism associated with Graves' orbitopathy","volume":"21","author":"Elbers","year":"2011","journal-title":"Thyroid"},{"key":"10.1016\/j.beem.2022.101631_bib43","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1507\/endocrj.K10E-262","article-title":"Drug discontinuation after treatment with minimum maintenance dose of an antithyroid drug in Graves' disease: a retrospective study on effects of treatment duration with minimum maintenance dose on lasting remission","volume":"58","author":"Konishi","year":"2011","journal-title":"Endocr J"},{"key":"10.1016\/j.beem.2022.101631_bib44","first-page":"1","article-title":"The longer the antithyroid drug is used, the lower the relapse rate in Graves' disease: a retrospective multicenter cohort study in Korea","author":"Park","year":"2021","journal-title":"Endocrine"},{"key":"10.1016\/j.beem.2022.101631_bib45","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12902-020-00670-w","article-title":"Control of Graves' hyperthyroidism with very long-term methimazole treatment: a clinical trial","volume":"21","author":"Azizi","year":"2021","journal-title":"BMC Endocr Disord"},{"key":"10.1016\/j.beem.2022.101631_bib46","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1507\/endocrj.EJ18-0418","article-title":"The long-term follow-up of patients with thionamide-treated Graves' hyperthyroidism","volume":"66","author":"Bandai","year":"2019","journal-title":"Endocr J"},{"key":"10.1016\/j.beem.2022.101631_bib47","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1089\/thy.2006.16.295","volume":"16","author":"Carella","year":"2006","journal-title":"Thyroid"},{"key":"10.1016\/j.beem.2022.101631_bib48","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1530\/eje.1.01993","article-title":"A\u00a0systematic review of drug therapy for Graves' hyperthyroidism","volume":"153","author":"Abraham","year":"2005","journal-title":"Eur J Endocrinol"},{"issue":"Suppl","key":"10.1016\/j.beem.2022.101631_bib49","doi-asserted-by":"crossref","DOI":"10.5812\/ijem.101473","article-title":"Remission rate of Graves' disease and the trend of changes in serum TSH receptor antibodies in prolonged antithyroid drug treatment","volume":"18","author":"Villagelin","year":"2020","journal-title":"Int J Endocrinol Metabol"},{"key":"10.1016\/j.beem.2022.101631_bib50","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1089\/thy.2019.0814","article-title":"Long-term treatment of hyperthyroidism with antithyroid drugs: 35 years of personal clinical experience","volume":"30","author":"Azizi","year":"2020","journal-title":"Thyroid"},{"key":"10.1016\/j.beem.2022.101631_bib51","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/cen.14374","article-title":"Comparison of long-term antithyroid drugs versus radioactive iodine or surgery for Graves' disease: a review of the literature","volume":"95","author":"El Kawkgi","year":"2021","journal-title":"Clin Endocrinol"},{"issue":"12","key":"10.1016\/j.beem.2022.101631_bib52","first-page":"4533","article-title":"Systemic thyroid hormone status during levothyroxine therapy in hypothyroidism: a systematic review and meta-analysis","volume":"103","author":"McAninch","year":"2018","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2022.101631_bib53","doi-asserted-by":"crossref","DOI":"10.5812\/ijem.95385","article-title":"Systemic thyroid hormone status in treated graves' disease","volume":"17","author":"Azizi","year":"2019","journal-title":"Int J Endocrinol Metabol"},{"key":"10.1016\/j.beem.2022.101631_bib54","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.jamcollsurg.2009.03.025","article-title":"Treatment options for Graves disease: a cost-effectiveness analysis","volume":"209","author":"In","year":"2009","journal-title":"J\u00a0Am Coll Surg"},{"key":"10.1016\/j.beem.2022.101631_bib55","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1530\/EJE-16-0527","article-title":"Cost-utility analysis comparing radioactive iodine, anti-thyroid drugs and total thyroidectomy for primary treatment of Graves' disease","volume":"175","author":"Donovan","year":"2016","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.beem.2022.101631_bib56","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1080\/08035250500252872","article-title":"Graves' disease in children and adolescents: response to long-term treatment","volume":"94","author":"Barrio","year":"2005","journal-title":"Acta Paediatr"},{"issue":"5\u20136","key":"10.1016\/j.beem.2022.101631_bib57","first-page":"257","article-title":"Comparison of methimazole and propylthiouracil in the management of children and adolescents with Graves' disease: efficacy and adverse reactions during initial treatment and long-term outcome","volume":"24","author":"Sato","year":"2011","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2022.101631_bib58","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1297\/cpe.26.1","article-title":"Relationship between dose of antithyroid drugs and adverse events in pediatric patients with Graves' disease","volume":"26","author":"Yasuda","year":"2017","journal-title":"Clin Pediatr Endocrinol"},{"key":"10.1016\/j.beem.2022.101631_bib59","doi-asserted-by":"crossref","first-page":"721","DOI":"10.3389\/fendo.2021.687834","article-title":"Long-term antithyroid drug treatment of Graves' disease in children and adolescents: a 20-year single-center experience","volume":"12","author":"Song","year":"2021","journal-title":"Front Endocrinol"},{"issue":"Suppl","key":"10.1016\/j.beem.2022.101631_bib60","first-page":"1","article-title":"Antithyroid drugs","volume":"18","author":"Abdi","year":"2019","journal-title":"Iran J Pharm Res (IJPR)"},{"issue":"Suppl","key":"10.1016\/j.beem.2022.101631_bib61","doi-asserted-by":"crossref","DOI":"10.5812\/ijem.101487","article-title":"Long-term treatment with antithyroid drugs: efficacy and safety","volume":"18","author":"Malboosbaf","year":"2020","journal-title":"Int J Endocrinol Metabol"},{"key":"10.1016\/j.beem.2022.101631_bib62","series-title":"Longman dictionary of contemporary English","author":"Procter","year":"1981"},{"key":"10.1016\/j.beem.2022.101631_bib63","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/S2213-8587(19)30059-2","article-title":"Primary therapy of Graves' disease and cardiovascular morbidity and mortality: a linked-record cohort study","volume":"7","author":"Okosieme","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"Suppl","key":"10.1016\/j.beem.2022.101631_bib64","doi-asserted-by":"crossref","DOI":"10.5812\/ijem.102269","article-title":"The concept of cure in thyroid diseases","volume":"18","author":"Azizi","year":"2020","journal-title":"Int J Endocrinol Metabol"},{"key":"10.1016\/j.beem.2022.101631_bib65","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1007\/s12020-017-1306-5","article-title":"Epidemiology, management and outcomes of Graves' disease\u2014real life data","volume":"56","author":"Hussain","year":"2017","journal-title":"Endocrine"},{"key":"10.1016\/j.beem.2022.101631_bib66","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1159\/000490384","article-title":"2018 European thyroid association guideline for the management of Graves' hyperthyroidism","volume":"7","author":"Kahaly","year":"2018","journal-title":"Eur Thyroid J"},{"key":"10.1016\/j.beem.2022.101631_bib67","doi-asserted-by":"crossref","first-page":"4439","DOI":"10.1210\/jc.2004-0247","article-title":"Propylthiouracil before 131I therapy of hyperthyroid diseases: effect on cure rate evaluated by a randomized clinical trial","volume":"89","author":"Bonnema","year":"2004","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2022.101631_bib68","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.jss.2017.06.091","article-title":"The long-term outcomes of thyroid function after subtotal thyroidectomy for Graves' hyperthyroidism","volume":"220","author":"Lin","year":"2017","journal-title":"J\u00a0Surg Res"},{"key":"10.1016\/j.beem.2022.101631_bib69","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/cen.13873","article-title":"Predicting outcomes and complications following radioiodine therapy in Graves' thyrotoxicosis","volume":"90","author":"Aung","year":"2019","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.beem.2022.101631_bib70","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0022552","article-title":"Levothyroxine monotherapy cannot guarantee euthyroidism in all athyreotic patients","volume":"6","author":"Gullo","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.beem.2022.101631_bib71","doi-asserted-by":"crossref","first-page":"4964","DOI":"10.1210\/jc.2016-2660","article-title":"Is a normal TSH synonymous with \u201ceuthyroidism\u201d in levothyroxine monotherapy?","volume":"101","author":"Peterson","year":"2016","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2022.101631_bib72","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1089\/thy.2015.0345","article-title":"Effects of levothyroxine replacement or suppressive therapy on energy expenditure and body composition","volume":"26","author":"Samuels","year":"2016","journal-title":"Thyroid"},{"key":"10.1016\/j.beem.2022.101631_bib73","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1046\/j.1365-2265.2002.01654.x","article-title":"Psychological well-being in patients on \u2018adequate\u2019doses of l-thyroxine: results of a large, controlled community-based questionnaire study","volume":"57","author":"Saravanan","year":"2002","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.beem.2022.101631_bib74","doi-asserted-by":"crossref","first-page":"R261","DOI":"10.1530\/EJE-18-0678","article-title":"Antithyroid drug therapy: 70 years later","volume":"179","author":"Burch","year":"2018","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.beem.2022.101631_bib75","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1097\/MED.0000000000000656","article-title":"Long-term antithyroid drug therapy","volume":"28","author":"Cooper","year":"2021","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"10.1016\/j.beem.2022.101631_bib76","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1210\/jc.2013-2409","article-title":"The incidence and prevalence of thyroid dysfunction in Europe: a meta-analysis","volume":"99","author":"Garmendia Madariaga","year":"2014","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2022.101631_bib77","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1161\/CIRCULATIONAHA.112.096024","article-title":"Subclinical thyroid dysfunction and the risk of heart failure events: an individual participant data analysis from 6 prospective cohorts","volume":"126","author":"Gencer","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.beem.2022.101631_bib78","series-title":"Subclinical thyroid disease and risk of new-onset atrial fibrillation","author":"Selmer","year":"2012"},{"key":"10.1016\/j.beem.2022.101631_bib79","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1210\/jc.2010-2693","article-title":"The Thyroid Epidemiology, Audit, and Research Study (TEARS): morbidity in patients with endogenous subclinical hyperthyroidism","volume":"96","author":"Vadiveloo","year":"2011","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2022.101631_bib80","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1007\/s12020-019-02110-9","article-title":"Association of subclinical thyroid dysfunction with bone mineral density and fracture: a meta-analysis of prospective cohort studies","volume":"67","author":"Zhu","year":"2020","journal-title":"Endocrine"},{"key":"10.1016\/j.beem.2022.101631_bib81","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1001\/archinternmed.2012.402","article-title":"Subclinical hyperthyroidism and the risk of coronary heart disease and mortality","volume":"172","author":"Collet","year":"2012","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.beem.2022.101631_bib82","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1159\/000438750","article-title":"The 2015 European Thyroid Association guidelines on diagnosis and treatment of endogenous subclinical hyperthyroidism","volume":"4","author":"Biondi","year":"2015","journal-title":"Eur Thyroid J"},{"key":"10.1016\/j.beem.2022.101631_bib83","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1089\/thy.2020.0433","article-title":"Treatment of subclinical hyperthyroidism in the elderly: comparison of radioiodine and long-term methimazole treatment","volume":"31","author":"Azizi","year":"2021","journal-title":"Thyroid"},{"key":"10.1016\/j.beem.2022.101631_bib84","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1056\/NEJMcp1709318","article-title":"Subclinical hyperthyroidism","volume":"378","author":"Biondi","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"Suppl","key":"10.1016\/j.beem.2022.101631_bib85","doi-asserted-by":"crossref","DOI":"10.5812\/ijem.102270","article-title":"A\u00a0new perspective in the management of Graves' hyperthyroidism","volume":"18","author":"Azizi","year":"2020","journal-title":"Int J Endocrinol Metabol"},{"key":"10.1016\/j.beem.2022.101631_bib86","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1089\/thy.2018.0397","article-title":"Treatment of toxic multinodular goiter: comparison of radioiodine and long-term methimazole treatment","volume":"29","author":"Azizi","year":"2019","journal-title":"Thyroid"},{"key":"10.1016\/j.beem.2022.101631_bib87","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1089\/thy.2018.0315","volume":"29","author":"T\u00f6rring","year":"2019","journal-title":"Thyroid"},{"key":"10.1016\/j.beem.2022.101631_bib88","doi-asserted-by":"crossref","first-page":"G43","DOI":"10.1530\/EJE-21-0479","article-title":"The 2021 European Group on Graves' orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves' orbitopathy","volume":"185","author":"Bartalena","year":"2021","journal-title":"Eur J Endocrinol"}],"container-title":["Best Practice & Research Clinical Endocrinology & Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521690X22000185?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521690X22000185?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T17:00:22Z","timestamp":1761498022000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521690X22000185"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":88,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["S1521690X22000185"],"URL":"https:\/\/doi.org\/10.1016\/j.beem.2022.101631","relation":{},"ISSN":["1521-690X"],"issn-type":[{"value":"1521-690X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term thionamide antithyroid treatment of Graves' disease","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Endocrinology & Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beem.2022.101631","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101631"}}